Kiltix

Quick links to important sections

Kiltix

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kiltix

Quick Facts

Property Description
Active Ingredients Flumethrin, Propoxur
Form Acaricide-impregnated collar (Solid Polymer Matrix)
Pharmacological Class Ectoparasiticide (Synthetic Pyrethroid and Carbamate)
Common Use Control and prevention of external parasitic infestations
Origin Synthetic

What Type of Medicine is Kiltix?

Kiltix is identified as a veterinary ectoparasiticide combination product formulated for external use exclusively on dogs. Its distinguishing characteristic is its dosage form as an acaricide-impregnated collar, a non-systemic, topical formulation engineered to provide continuous parasitic control. The collar's design ensures a controlled, long-term release of the active components, allowing for the sustained efficacy of the collar formulation over several months. This unique formulation provides a key differentiator from single-application treatments.

The Dual-Action Synthetic Composition of Kiltix

The efficacy of this combination product relies on two distinct synthetic active ingredients: Propoxur and Flumethrin. Propoxur is chemically classified as a carbamate insecticide, while Flumethrin belongs to the synthetic pyrethroid class. The strategic pairing of these two neurotoxic agents within the collar’s solid polymer matrix is pharmacologically intended to establish a synergistic effect, thereby enhancing the overall efficacy against the target parasites.

General Purpose: Long-Term External Parasite Control

The primary purpose of Kiltix is the effective control and prevention of parasitic infestations on the animal's exterior. The product’s unique contact action mechanism relies on the gradual migration of the active agents from the collar across the skin surface, affecting the parasite upon exposure. This sustained dual-action mechanism provides high immediate and residual efficacy against hard ticks and other ectoparasites, offering a long-term external solution for routine parasite management.

What side effects are possible with Kiltix?

Possible Side Effects and Safety Information

The safety profile for the Kiltix collar is defined by classifications and constraints established in government regulatory documentation. Adverse reactions are grouped by frequency, system effects, and the potential for toxicity from improper exposure.

Adverse Reaction Scope

Category Regulatory Description
Application-Site Reactions Mild, localized effects such as pruritus (itching) or erythema (redness) are generally classified as Uncommon or Very Rare. These local reactions may be more common in the first few days following initial application.
Systemic Signs Signs associated with accidental oral exposure (chewing or ingestion) of the collar material include vomiting, salivation, and other gastrointestinal or neurological effects, which are also classified as Very Rare.
Serious Adverse Reactions Regulatory documents note the potential for signs of carbamate poisoning (e.g., severe salivation, neurological disturbances) if the collar is chewed or swallowed, which represents the most significant toxicity hazard.

Mandatory Safety Constraints

The official labeling includes explicit conditions that restrict use of the product:

  • Population-Specific Contraindications: Use is strictly contraindicated in puppies under 12 weeks of age and in animals that are sick or convalescing (debilitated). Safety has not been established for use during pregnancy or lactation.
  • Drug Restrictions: The product must not be used simultaneously with other anti-parasitic preparations that contain organophosphates.
  • Health Restrictions: The collar is contraindicated for use in dogs with extensive skin lesions or in animals with known hypersensitivity to either active substance, Propoxur or Flumethrin.

This structure ensures that potential risks are organized based on regulatory definitions and specific limitations for appropriate use.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose or accidental systemic exposure to the active ingredients (Propoxur and Flumethrin) can result in a dual neurotoxic syndrome, as documented by official regulatory sources.

Element
Documented Overdose Manifestations Symptoms include excessive hypersalivation, vomiting, sweating, and muscle twitching (fasciculations) from the carbamate component, and paresthesia (tingling), dizziness, or ataxia from the pyrethroid component.
Severe Outcomes Life-threatening manifestations can involve severe convulsions, coma, and respiratory distress, including the potential for non-cardiogenic pulmonary oedema.

Required Emergency Actions

Action
When Immediate Medical Help is Required Urgent medical attention is mandated immediately upon the presentation of any severe or persistent symptoms, or in cases involving breathing distress, loss of consciousness, or seizures. Prompt transfer to a medical facility is required for severe poisoning.
Treatment Protocols Supportive and symptomatic measures are required. Atropine is documented for managing severe muscarinic effects. Official guidance generally contraindicates Pralidoxime (2-PAM) and advises caution against inducing vomiting.
Population-Specific Note Official risk assessments state that accidental exposure may pose unacceptable risks to children, necessitating immediate professional evaluation.

Accidental exposure requires immediate removal of contaminated clothing and washing of the skin. The official regulatory profile is defined by these specific neurotoxic effects and mandates rapid, specific emergency responses and management, particularly given the potential for severe CNS and respiratory failure.

Therapeutic Uses of Kiltix

Kiltix is a veterinary medicinal product primarily used for the treatment and sustained prevention of external parasites in dogs. Its core therapeutic purpose is managing conditions associated with external parasitic burden.

The product is classified as an Antiparasitic and is used for external parasite management. The combination of Flumethrin and Propoxur is commonly used for managing conditions involving certain distressing symptoms caused by external parasites. This product is used across therapeutic domains where additional symptomatic support is needed for external parasite management, including: Maintaining control and prevention of common ticks (like Brown Dog and Wood Ticks), managing flea infestations (Ctenocephalides spp.), and offering supportive use against the medically significant Paralysis Tick.

By managing these ectoparasites, Kiltix helps to relieve associated symptoms related to physical discomfort like itching (pruritus) and skin irritation, which are symptoms that interfere with daily functioning. The collar is applied in clinical settings that involve acute or unstable symptom patterns, supporting the animal during difficult episodes by easing the overall symptom load related to potential severe, systemic burden.

Quick Fact: Relief for Skin Discomfort
Symptom Category: Symptoms related to inflammatory or irritative states.
Benefit Focus: Assists with maintaining functional stability by easing the symptoms related to irritative states.
Typical Context: Applied during phases of increased distress caused by external parasitic activity.

Regulatory References

  1. FDA Philippines Veterinary Drugs View

Eligibility and Restrictions for Use

Eligibility for Kiltix Use (Flumethrin and Propoxur Collar)

Official regulatory documents define strict population eligibility criteria for the use of Kiltix, focusing on the target species, age, and systemic health status of the animal.

Category Official Regulatory Classification
Target Species Allowed: Dogs only.
Non-Eligible Species Contraindicated: Cats and other non-target animals.
Age Restriction Contraindicated: Puppies under three months (12 weeks) of age.
Health Status Contraindicated: Dogs that are sick, convalescing (recovering), or have extensive skin lesions.
Active Ingredient Contraindicated: Dogs with known hypersensitivity to Propoxur, Flumethrin, or any excipients.

Use is prohibited for dogs concurrently being treated with other anticholinesterase-based products (e.g., organophosphates). Furthermore, some regulatory labels list contraindications for dogs with certain severe pulmonary, cardiovascular, or gastrointestinal obstructive conditions due to the Propoxur component. Safety has not been established for use in pregnant or lactating (nursing) dogs, classifying this population as restricted use only.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation identifies a specific restriction concerning the concurrent use of the collar's active ingredient, propoxur, with other medicinal products of a particular chemical class.

Interacting Product Category Regulatory Constraint
Anticholinesterase Pesticides Do not use concurrently with this product.
Organophosphate-Based Products Contraindicated for use in animals receiving these treatments.

This constraint is based on the shared mechanism of action between the collar's ingredient (a carbamate) and other anticholinesterase agents, such as organophosphates. Co-administration is strictly prohibited to prevent additive effects that may result in toxicity.

The regulatory labels explicitly state that the product is contraindicated for use with any other anticholinesterase pesticide while the collar is worn, and that it should not be used on animals undergoing treatment with any other organophosphate-based products. This includes various forms of treatment such as rinses, shampoos, sprays, collars, and oral formulations. The documented interaction profile is therefore tightly focused on avoiding combinations with products that exert this specific pharmacological action.

Mechanism of Action

The mechanism of Kiltix involves a non-systemic, dual-action neurotoxicity that targets two distinct, essential functions of the arthropod nervous system, leading to a profound and sustained compromise of physiological function.

Disruption of Synaptic Signal Termination (Propoxur)

This action engages the cholinergic pathway by acting as an inhibitor of the Acetylcholinesterase (AChE) enzyme. This prevents the breakdown of the neurotransmitter acetylcholine, leading to its massive accumulation in the synaptic cleft, which causes the initial phase of uncontrolled hyper-excitation in the ectoparasite.

Prevention of Nerve Impulse Repolarization (Flumethrin)

The second mechanistic domain involves the modulation of Voltage-Gated Sodium Channels (VGSCs) in nerve membranes by Flumethrin. By binding to and stabilizing the channel in its open state, the drug causes persistent membrane depolarization and an uninterrupted flow of nerve impulses, which leads directly to the final phase of loss of motor function and paralysis.

Mechanistic Synergy and Functional Collapse

The combination of both agents provides a strategic, non-competitive attack. The dual mechanism compromises both the chemical control of the signal (Propoxur) and the electrical propagation of the signal (Flumethrin) simultaneously. This coordinated failure of the arthropod's central and peripheral nervous systems results in functional collapse of the nervous system.

Dosage and Administration Information

How to Use Kiltix

Kiltix is administered strictly via a cutaneous/topical route as an acaricide-impregnated collar, confirming its designation as a non-systemic external treatment. The standard dosing schedule requires the application of one collar per animal around the neck, where the collar serves as the single-unit dose. This dosage is fixed and made available in specific collar lengths designed to accommodate varying dog sizes.

The primary administration requirement is the Continuous Wear Regimen. The collar must be worn constantly throughout the duration of the treatment course. This continuous schedule provides sustained release of the active ingredients, with the standard course duration requiring the collar to be removed and replaced with a new unit after a period typically ranging from six to seven months.

Proper application involves a specific procedural structure to ensure correct administration. The appropriate collar size, often determined by the dog's weight, must first be selected. When applying the unit, it is necessary to adjust the fit to ensure approximately two fingers can easily slide between the collar and the dog’s neck. Once fitted, any excess collar length beyond roughly two centimeters should be trimmed and disposed of.

The usage protocol includes special procedural conditions related to maintenance. The product's efficacy may be reduced by prolonged or extensive exposure to water or frequent shampooing. Furthermore, the collar's fit must be checked periodically to prevent displacement, which is particularly important for animals undergoing rapid growth. This procedural structure defines a standardized, long-term external solution requiring adherence to a fixed replacement cycle.

Recent Clinical Evidence

Research evidence / Overview of studies for Kiltix

The research evidence for the Kiltix collar, which contains flumethrin and propoxur, is rooted in controlled trials and laboratory studies that were required for regulatory evaluation. This evidence base describes how the collar was studied regarding external parasitic burdens and the duration of observed patterns. The studies are often conducted under specific, controlled conditions to allow for precise measurement of outcomes.


Evidence for use in Controlling Tick Infestations

Research has explored how the collar was studied primarily against hard ticks, such as the Brown Dog Tick (Rhipicephalus sanguineus). These investigations often involved Randomized Controlled Trials (RCTs) conducted in kennelled dogs, which allowed for the monitoring of outcomes under consistent, regulated circumstances.

What was studied: Researchers primarily focused on two key outcomes: the effect on tick counts (the measured variable of live attached tick counts following application) and the residual effect over time against repeated re-infestations. The specific time to initial action and the sustained duration of measured activity were key parameters examined.

What the studies reported: Findings describe patterns observed in these studies where measurements related to tick counts were taken on dogs within a few days of fitting the collar. Research described measurements taken related to patterns of sustained activity against ticks, with this pattern observed across multiple challenge periods extending up to 5 to 7 months in controlled settings.


Evidence for use in Managing Flea Infestations

The combination product was also studied regarding its evaluation against flea infestations, specifically those caused by common species like Ctenocephalides felis and C. canis.

What was studied: Studies were conducted during periods of increased symptom activity from the fleas, monitoring measurements related to the flea population on the animal. Outcomes monitored included the effect on flea counts (the measured variable of the live flea population count) and the duration of residual protection against new flea challenges over time.

What remains uncertain: While the studies monitored these patterns, the primary focus of the regulatory evidence base often emphasizes the tick control outcomes. Consequently, dedicated, high-level research summaries or meta-analyses focusing solely on the long-term flea-killing duration of this specific combination may be less prevalent than for the main tick indication.


Durability of Effect and Long-Term Study Periods

How the collar was studied regarding its formulation involved examining the continuous release of the active ingredients, making the duration of measured patterns a primary subject of research.

What the studies reported: Findings indicate that a sustained pattern of measured activity was observed across the entire monitoring period in the dogs studied. However, research describes that factors such as the dog's coat condition, external environment, and local parasitic pressure may influence the measured durability of the effect.


Research Gaps and Areas of Uncertainty

Research highlights what is known—and what is still uncertain. Comparative evidence is lacking for how this specific collar formulation performs against newer systemic or topical products in recent, large-scale, head-to-head trials. Furthermore, certainty remains low regarding performance across the full range of field conditions, as these variables can be difficult to fully replicate and standardize in regulatory-grade studies. Findings describe group patterns, not personal outcomes.

Key Studies & References FDA Philippines Veterinary Drugs View (Official product classification reference provided in initial context)

Frequently Asked Questions (FAQ)

Common questions about Kiltix (FAQ)


Q: How quickly can a person expect to see the effects of Kiltix after starting to use it?

Studies and official product information indicate that the collar begins to affect the target parasites immediately upon proper fitting. Measured efficacy (the ability to kill or repel parasites) in controlled studies often showed rapid initial measured efficacy against the target parasites within the first two days of application in controlled studies.


Q: Why are people talking about Kiltix and a certain other medicine together?

Official documents address the interaction risk with other medicinal products. Official regulatory information strictly advises against the concurrent use of the collar with other organophosphate-based or anticholinesterase-based products. This mandatory safety constraint is in place to prevent additive effects that could potentially lead to toxicity.


Q: What is the difference between Kiltix and [A common similar drug name]?

The official product information describes Kiltix as an external, non-systemic collar. It provides a continuous, dual-action mechanism using a combination of two synthetic active ingredients: flumethrin and propoxur. This formulation, providing sustained release directly on the animal's exterior, defines its key characteristics compared to other product types.


Q: Are there different types or strengths of Kiltix available?

According to official documents, the collar is manufactured in specific lengths or sizes. These variations are designed to accommodate different dog sizes and ensure the proper fit necessary for the sustained release of the active ingredients.


Q: What is the significance of the research evidence mentioned for Kiltix?

The research evidence, including controlled trials, was necessary for the official regulatory evaluation and acceptance of the product. These studies describe the patterns of effect and the sustained duration of activity, which support the product’s intended use and official claims.


Q: Why does the official leaflet list so many possible side effects for Kiltix?

Regulatory requirements state that all observed adverse reactions, regardless of how frequently they occur, must be officially categorized and listed in the product documents. This ensures that users are informed of all potential effects, even those classified as Uncommon or Very Rare.


Q: If a dose of Kiltix is missed, what should be done?

Official documents emphasize that the collar provides a continuous, sustained release of active ingredients and is intended for uninterrupted wear. The concept of a 'missed dose' is not applicable to this continuous-release formulation, but rather to the replacement of the collar unit after the specified long-term duration.


Q: What age group is Kiltix generally intended for, based on official documents?

Official regulatory documents establish strict eligibility criteria for use. The collar is strictly contraindicated for use in puppies under 12 weeks of age. This means the product is generally intended for use on dogs that meet or exceed this minimum age requirement.


Q: What is the experience of patients who use Kiltix long-term, according to studies?

Studies used for regulatory evaluation focused on the measured durability of the product's effect in controlled settings. These investigations monitored the sustained patterns of antiparasitic activity across the entire study period, which can extend up to seven months.


Q: Can Kiltix be used with other treatments for [Disease the drug treats]?

Official product information strictly advises against combining the collar with other anti-parasitic products that contain organophosphates or similar anticholinesterase agents. This is a mandatory safety constraint listed in the regulatory documentation.


Q: Is it normal for a person to still experience symptoms while taking Kiltix?

Research evidence describes that while the product shows sustained activity in controlled settings, certainty regarding performance remains low across the full range of variable field conditions. This suggests that non-zero infestations may still occur in real-world environments due to factors that are difficult to standardize.


Q: Why does Kiltix have restrictions for people with a history of heart problems?

The regulatory contraindication is specific to dogs and not people. This restriction is related to the Propoxur component and is included for animals with certain severe underlying conditions, including pulmonary, cardiovascular, or gastrointestinal obstructive conditions.


Q: Are the side effects of Kiltix worse when a person first starts taking it?

Official safety information indicates that local reactions, such as mild redness or itching (pruritus) at the collar site, may be observed more frequently during the initial few days of application. These reactions are typically classified as uncommon or very rare.


Q: Do regulatory bodies consider Kiltix to be highly effective?

Regulatory evaluations relied on research that describes high immediate and residual measured efficacy against the target parasites. These patterns were observed in controlled study settings required for official product approval.


Q: What makes Kiltix different from older treatments for the same condition?

The official product information describes Kiltix as an external, non-systemic collar. It provides a continuous, dual-action mechanism using a combination of two synthetic active ingredients: flumethrin and propoxur. This formulation, providing sustained release directly on the animal's exterior, defines its key characteristics compared to other product types.


Q: What are the signs of an informational drug interaction involving Kiltix?

The prohibited interaction with other anticholinesterase agents can result in toxicity. The signs of this condition are expected to resemble those of carbamate poisoning, which can include severe salivation, vomiting, and neurological disturbances.


Q: How does a person know if Kiltix is the right treatment approach for them?

The determination of whether the product is appropriate is based on meeting the regulatory-defined eligibility criteria. Official documents define the minimum age, target species (dogs only), and contraindications related to overall health status that must be met.


Q: Is Kiltix used for anything other than what is listed in the main section?

According to official documents, the labeled purpose of Kiltix is the control and prevention of specific species of external parasites. This primary indication includes ticks and fleas, and in some regions, the labeled use is expanded to include lice infestations.


Q: Does Kiltix have different instructions for use in older adults?

Regulatory documents define a strict age contraindication for puppies under 12 weeks. However, official product information does not list any unique or modified instructions specifically for senior or older dogs.


Q: Can Kiltix be used by people who have a sensitive stomach?

Official regulatory documents designate this product exclusively for use on dogs. It is classified as a veterinary ectoparasiticide for external application only.


Q: Are there any specific foods or drinks that should be avoided when using Kiltix?

Official regulatory documents regarding the use of the collar do not list any specific food or drink restrictions that must be observed while the product is being worn.


Q: Is it normal to feel tired after starting Kiltix?

Regulatory safety information indicates that lethargy (tiredness) is not routinely listed as a side effect from correct use in dogs. However, signs like lethargy and drowsiness are noted as potential, but rare, effects if the collar is accidentally chewed or ingested.


Q: Does the time of day a person uses Kiltix matter?

Regulatory instructions for the collar specify a continuous wear regimen to ensure the sustained release of the active ingredients. The official documents do not specify an optimal time of day for the initial application.


Q: Are there any known issues with using Kiltix during very hot or cold weather?

Regulatory documents primarily address the reduction of efficacy due to external factors, noting that prolonged or extensive exposure to water or frequent shampooing may reduce the product's effectiveness.


Q: Does Kiltix interact with common over-the-counter pain relievers?

The official interaction profile listed in regulatory documents is narrowly focused on avoiding concurrent use with other products that share a specific anticholinesterase mechanism of action, such as organophosphate-based products.


Q: Is Kiltix appropriate for individuals with kidney issues?

Official regulatory documents designate this product exclusively for use on dogs. It is classified as a veterinary ectoparasiticide for external application only.


Q: Can Kiltix affect mental focus or concentration?

If ingested or severely mishandled, the propoxur component may lead to neurological effects, including drowsiness, as described in product safety information. The product is not intended to affect focus or concentration with proper use.


Q: How is Kiltix classified by health authorities (e.g., prescription only, controlled substance)?

Official regulatory documents specify the product’s classification status. In some regions, the collar is classified as a veterinary product that is available only with a prescription.


Q: Does Kiltix interact with common supplements like multivitamins or herbal remedies?

The official interaction profile listed in regulatory documents is narrowly focused on avoiding concurrent use with other products that share a specific anticholinesterase mechanism of action, such as organophosphate-based products.


Q: Is Kiltix safe for people with liver disease?

Official regulatory documents designate this product exclusively for use on dogs. It is classified as a veterinary ectoparasiticide for external application only.


Q: Does Kiltix interact with alcohol?

The official interaction profile listed in regulatory documents does not provide any specific restrictions or information regarding concurrent use with alcohol.


Q: What does it mean that Kiltix has a 'boxed warning' or 'special warning'?

Official documents highlight the potential for signs of carbamate poisoning if the collar is chewed or swallowed, which represents the most significant mandatory safety constraint.


Q: If Kiltix is stopped suddenly, are there any expected effects?

Since the product's function is to provide long-term, continuous parasitic treatment, stopping its use abruptly would result in the immediate loss of sustained control against ectoparasites. No other effects of abrupt cessation are noted in regulatory information.


Q: Is Kiltix known to cause any long-term health issues?

Regulatory testing examined the active ingredients to assess the potential for long-term health effects. These evaluations found that the active ingredients have not been shown to produce reproductive, mutagenic, or carcinogenic effects.


Q: Can Kiltix affect blood pressure readings?

While the Propoxur component includes a contraindication related to severe cardiovascular obstructive conditions in the animal, there is no explicit effect on routine blood pressure listed as a side effect in regulatory documents.


Q: Does using Kiltix require regular medical check-ups or monitoring?

Regulatory instructions emphasize the importance of checking the collar’s fit periodically to prevent displacement. Furthermore, the instructions note that the collar should be removed if persistent skin reactions or unusual behavior occur.

How should Kiltix be stored and disposed of?

Official Storage and Disposal Instructions

Kiltix must be stored below 30 C and protected from excessive heat (above 40 C) and moisture. The product should be stored in its original container and must not be removed from the inner envelope until it is ready for immediate application. Official labeling requires the product to be kept out of reach of children and away from food or animal feed.

Storage Condition Requirement
Temperature Range Store below 30 C; avoid heat above 40 C.
Protection Protect from moisture and heat.
Container Rule Keep in original container; do not open inner envelope until use.

For disposal, regulatory documents classify Kiltix and its container as hazardous waste due to its composition. Unused or expired product must not be released into the environment, including soil, drains, or waterways, and must be disposed of according to local regulations for hazardous materials.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Kiltix found in:

A-Z Index: